Timing of Evolocumab Initiation After Acute Coronary Syndrome and Long-Term Lipid and Cardiovascular Outcomes: A Multicenter Real-World Cohort Study
Pharmaceuticals · 02.07.2026 · 19 (7) · 1035
DOI: 10.3390/ph19071035 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pharmaceuticals, online erschienen am 02.07.2026. Verfasst von Lama Alfehaid und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.
Abstract (Originalsprache)
Background
Intensive low-density lipoprotein cholesterol (LDL-C) reduction is essential for secondary prevention after acute coronary syndrome (ACS). Although randomized trials support the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, real-world evidence on long-term lipid control and the optimal timing of initiation remains limited.
Objective
To evaluate lipid outcomes and atherosclerotic cardiovascular disease (ASCVD) events associated with evolocumab after ACS and to assess whether timing of initiation influences these outcomes in routine clinical practice.
Methods
This multicenter, retrospective cohort study included adults who were initiated on evolocumab following ACS between 2017 and 2024. Lipid parameters were assessed at predefined follow-up time points (3 months, 6 months, 1 year, 2 years, and up to 3 years) using an available-case approach. Patients were categorized as early initiators (≤1 month) or late initiators (>1 month). Recurrent ASCVD events, hospitalization burden, and mortality were analyzed using multivariable regression. A propensity score-matched sensitivity analysis was also performed.
Results
Among 525 included patients (mean age 53.1 ± 11.6 years; 80.2% male), baseline LDL-C was 3.68 ± 1.66 mmol/L. LDL-C decreased to approximately 1.8–2.0 mmol/L within 3 months, corresponding to an approximate 45–50% reduction from baseline, with consistent reductions observed across available follow-up time points. Recurrent ASCVD events occurred in 14.8% of patients, and in-hospital mortality was 2.3%. Although early initiators had higher baseline risk, adjusted analyses showed no statistically significant association between early initiation and recurrent ASCVD (adjusted OR 1.50; 95% CI 0.82–2.70; p = 0.17). Similarly, no statistically significant differences in lipid outcomes were observed between early and late initiation groups after adjustment. Findings were consistent in propensity score-matched analyses.
Conclusions
In this real-world post-ACS cohort, evolocumab was associated with substantial and sustained LDL-C reduction across follow-up time points. No significant associations were observed between timing of initiation and lipid or ASCVD outcomes after adjustment. These findings should be interpreted cautiously, given the observational design, available-case analysis, and potential for residual confounding.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy Practice, College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh 14611, Saudi Arabia.
- King Abdullah International Medical Research Center, Riyadh 11481, Saudi Arabia.
- Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh 14611, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Taibah University, Madinah 42353, Saudi Arabia.
- Prince Mohammad Bin Abdulaziz Hospital, National Guard Health Affairs, Madinah 42324, Saudi Arabia.
- Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh 11671, Saudi Arabia.
ORCID-Profile: Lama Alfehaid, Ehsan A Habeeb, Salwa A Alsuhaibani, Hanan Alfulayyih, Majed S Al Yami
Förderung
- Princess Nourah bint Abdulrahman University
Zitieren
APA
Alfehaid, L., Habeeb, E. A., Badawoud, A. M., Alsuhaibani, S. A., Almutairi, R., Alyahya, R., Alquraishi, S., Alharbi, H., Alshammari, S., Alfulayyih, H., Almasoud, W., Almakrami, A. A., Almutairi, A., & Al Yami, M. S. (2026). Timing of Evolocumab Initiation After Acute Coronary Syndrome and Long-Term Lipid and Cardiovascular Outcomes: A Multicenter Real-World Cohort Study. Pharmaceuticals, 19(7), 1035. https://doi.org/10.3390/ph19071035
Vancouver
Alfehaid L, Habeeb EA, Badawoud AM, Alsuhaibani SA, Almutairi R, Alyahya R, et al. Timing of Evolocumab Initiation After Acute Coronary Syndrome and Long-Term Lipid and Cardiovascular Outcomes: A Multicenter Real-World Cohort Study. Pharmaceuticals. 2026;19(7):1035. doi:10.3390/ph19071035
BibTeX
@article{Alfehaid2026,
author = {Alfehaid, Lama and Habeeb, Ehsan A and Badawoud, Amal M and Alsuhaibani, Salwa A and Almutairi, Rasha and Alyahya, Rafeef and Alquraishi, Shoug and Alharbi, Hanin and Alshammari, Sara and Alfulayyih, Hanan and Almasoud, Waad and Almakrami, Ali A and Almutairi, Abdulaali and Al Yami, Majed S},
title = {Timing of Evolocumab Initiation After Acute Coronary Syndrome and Long-Term Lipid and Cardiovascular Outcomes: A Multicenter Real-World Cohort Study},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {7},
pages = {1035},
doi = {10.3390/ph19071035}
}
EUVIMED